REGISTER
Teva’s Novel Migraine Drug Approved in China
On June 8, 2025, China’s NMPA approved Teva’s fremanezumab for migraine prevention. As the world‘s first approved CGRP monoclonal antibody, it selectively binds to the CGRP ligand. The approval was based on a positive Phase III double-blind study in China, which met all primary and secondary endpoints, significantly reducing monthly migraine days with a favorable safety profile.

On June 8, the official website of the National Medical Products Administration (NMPA) showed that Teva’s fremanezumab injection (formerly known as eptinezumab) was approved for the preventive treatment of migraine.

Fremanezumab is a humanized monoclonal antibody (mAb) that selectively binds to the calcitonin gene-related peptide (CGRP) ligand. Fremanezumab was the first CGRP monoclonal antibody approved globally.

In April 2024, Teva announced that in a Phase III double-blind study in China, 365 adult subjects were randomly assigned in a 1:1:2 ratio to three treatment groups: monthly subcutaneous injection of fremanezumab at a dose of 225 mg for three months, quarterly subcutaneous injection at a dose of 675 mg, and a placebo group.

In this study, fremanezumab successfully achieved the primary endpoint and all secondary endpoints, with a significant reduction in monthly migraine days and superior efficacy compared with placebo. Study data also demonstrated that fremanezumab had a good safety and tolerability profile, with no safety signals identified.

Fremanezumab was approved in the United States in 2018 and in the European Union in 2019 for the preventive treatment of migraine in adult patients. In 2023, it was authorized by the Guangdong Medical Products Administration to be implemented in the Guangdong-Hong Kong-Macao Greater Bay Area under the “Hong Kong and Macao Drug and Device Access” policy, allowing patients to receive treatment at designated medical institutions in the Greater Bay Area such as Guangzhou United Family Hospital, Nansha Branch of Guangzhou First People's Hospital, and Sun Yat-sen Memorial Hospital of Sun Yat-sen University. In January 2025, the marketing application for fremanezumab was accepted by the Center for Drug Evaluation (CDE).

Migraine attacks cause debilitating pain, nausea, vomiting, and sensitivity to light and sound, severely impacting patients’ ability to perform daily tasks. The burden of migraine and the fear of subsequent attacks can have a significant negative impact on quality of life, including family, social, and occupational relationships. Compared with healthy individuals, people with migraine are more likely to suffer from anxiety and depression.

0
0
Loading